U.S. Stem Cell (USRM) 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 30, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BIOHEART, INC.	'
Entity Central Index Key	'0001388319	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	347,175,310

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$6,684	'
Accounts receivable, net	8,895	1,342
Inventory	'	62,953
Prepaid and other	'	41,533
Total current assets	15,579	105,828
Property and equipment, net	492	1,820
Other assets	54,662	54,662
Total assets	70,733	162,310
Current liabilities:	'	'
Bank overdraft	'	89
Accounts payable	2,407,463	2,556,043
Accrued expenses	4,530,681	4,731,488
Advances, related party	316,198	313,448
Deposits	465,286	465,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	2,330,324	2,215,324
Notes payable, net of debt discount	1,890,410	2,364,972
Total current liabilities	13,440,362	14,146,650
Long term debt:	'	'
Derivative liability	281,037	611,227
Stockholders' deficit:	'	'
Preferred stock, par value $0.001; 20,000,000 and 5,000,000 shares authorized as of September 30, 2013 and December 31, 2012, respectively, 20,000,000 and -0- issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	20,000	'
Common stock, par value $0.001; 950,000,000 and 195,000,000 shares authorized as of September 30, 2013 and December 31, 2012, respectively, 319,315,563 and 182,062,802 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	319,316	182,063
Additional paid in capital	103,113,742	100,260,094
Common stock subscription	350,000	'
Deficit accumulated during development stage	-117,453,724	-115,037,724
Total stockholders' deficit	-13,650,667	-14,595,567
Total liabilities and stockholders' deficit	$70,733	$162,310

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	5,000,000
Preferred stock, shares issued	20,000,000	0
Preferred stock, shares outstanding	20,000,000	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	950,000,000	195,000,000
Common stock, shares issued	319,315,563	182,062,802
Common stock, shares outstanding	319,315,563	182,062,802

Condensed_Statements_of_Operat

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Statements of Operations [Abstract]	'	'	'	'	'
Revenue	'	$4,072	'	$47,245	$1,269,640
Cost of sales	'	'	'	417	551,904
Gross profit	'	4,072	'	46,828	717,736
Operating expenses:	'	'	'	'	'
Research and development	158,381	106,889	494,762	297,535	65,187,814
Marketing, general and administrative	940,354	677,950	1,750,276	1,571,288	38,588,112
Impairment of investment	'	'	'	'	58,695
Depreciation and amortization	77	3,377	1,327	11,570	899,241
Total operating expenses	1,098,812	788,216	2,246,365	1,880,393	104,733,862
Net loss from operations	-1,098,812	-784,144	-2,246,365	-1,833,565	-104,016,126
Other income (expenses):	'	'	'	'	'
Development revenues	'	'	'	'	117,500
Gain on settlement of debt	'	'	1,004,224	'	1,004,224
Gain on change of fair value of derivative liability	129,298	20,804	39,885	27,265	134,654
Interest income	'	'	'	'	762,277
Other income	31,659	819	56,919	18,234	327,984
Interest expense	-208,914	-342,022	-1,270,663	-1,023,654	-15,784,237
Total other income (expenses)	-47,956	-320,399	-169,635	-978,155	-13,437,598
Net loss before income taxes	-1,146,769	-1,104,543	-2,416,000	-2,811,720	-117,453,724
Income taxes (benefit)	'	'	'	'	'
NET LOSS	($1,146,769)	($1,104,543)	($2,416,000)	($2,811,720)	($117,453,724)
Net loss per common share, basic and diluted	($0.01)	($0.01)	($0.01)	($0.02)	'
Weighted average number of common shares outstanding, basic and diluted	246,229,899	155,968,821	217,392,664	135,812,320	'

Condensed_Statement_of_Stockho

Condensed Statement of Stockholders' Deficit (Unaudited) (USD $)	Total	Preferred stock	Common stock	Additional paid in capital	Subscription Receivable	Deficit accumulated during development stage
Beginning Balance at Dec. 31, 2012	($14,595,567)	'	$182,063	$100,260,094	'	($115,037,724)
Beginning Balance, Shares at Dec. 31, 2012	'	'	182,062,802	'	'	'
Reclassify the fair value of excess committed shares liability to equity upon common share authorization increase	474,954	'	'	474,954	'	'
Issuance of common stock	550,000	'	29,777	520,223	'	'
Issuance of common stock, Shares	'	'	29,776,525	'	'	'
Common stock issued under put agreement	200,000	'	12,659	187,341	'	'
Common stock issued under put agreement, Shares	'	'	12,658,545	'	'	'
Common stock issued in connection with issuance of convertible debt	36,250	'	2,500	33,750	'	'
Common stock issued in connection with issuance of convertible debt, Shares	'	'	2,500,000	'	'	'
Common stock issued in connection with settlement of debt	575,463	'	39,834	535,629	'	'
Common stock issued in connection with settlement of debt, Shares	'	'	39,833,771	'	'	'
Common stock issued for services	40,519	'	2,532	37,987	'	'
Common stock issued for services,Shares	'	'	2,532,471	'	'	'
Common stock issued in settlement of related party notes payable	537,750	'	44,890	492,860	'	'
Common stock issued in settlement of related party notes payable,Shares	'	'	44,890,348	'	'	'
Common stock issued in settlement of accounts payable	149,240	'	5,061	144,179	'	'
Common stock issued in settlement of accounts payable, Shares	'	'	5,061,101	'	'	'
Preferred stock issued in settlement of debt	70,000	5,000	'	65,000	'	'
Preferred stock issued in settlement of debt, Shares	'	5,000,000	'	'	'	'
Preferred stock issued in settlement of forbearance agreement	274,050	15,000	'	259,050	'	'
Preferred stock issued in settlement of forbearance agreement, Shares	'	15,000,000	'	'	'	'
Proceeds from common stock subscription	365,000	'	'	'	350,000	'
Stock based compensation	102,674	'	'	102,674	'	'
Net loss	-2,416,000	'	'	'	'	-2,416,000
Balance at Sep. 30, 2013	($13,650,667)	$20,000	$319,316	$103,113,742	$350,000	($117,453,724)
Balance, Shares at Sep. 30, 2013	'	20,000,000	319,315,563	'	'	'

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($2,416,000)	($2,811,720)	($117,453,724)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	1,328	11,570	899,242
Bad debt expense	'	'	166,266
Discount on convertible debt	295,750	382,693	1,907,318
Loss (gain) on change in fair value of derivative liability	-39,885	-27,265	-134,654
Gain on settlement of debt	-1,004,224	'	-1,004,224
Non cash payment of interest	168,350	36,251	439,462
Amortization of warrants issued in exchange for licenses and intellectual property	'	'	5,413,156
Amortization of warrants issued in connection with notes payable	'	95,291	5,437,604
Amortization of loan costs	'	927	1,228,717
Related party notes payable issued for services rendered	500,000	'	500,000
Warrants issued in exchange for services	'	'	285,659
Warrants issued in exchange for forbearance agreement	'	119,023	430,213
Equity instruments issued in connection with R&D agreement	'	'	360,032
Equity instruments issued in connection with settlement agreement	'	'	3,381,629
Common stock issued in connection with accounts payable	2,500	'	759,316
Common stock issued in exchange for services	40,519	34,600	1,523,041
Common stock issued in connection with amounts due to guarantors of Bank of America loan	'	'	69,159
Common stock issued in exchange for distribution rights and intellectual property	'	'	99,997
Preferred stock issued in settlement of forbearance agreement penalty	274,050	'	274,050
Warrants issued in connection with accounts payable	'	'	7,758
Stock based compensation	102,674	56,476	10,053,676
(Increase) decrease in:	'	'	'
Receivables	-7,553	2,379	-10,160
Inventory	62,953	417	-1
Prepaid and other current assets	41,533	-21,169	-9,969
Other assets	0	0	-28,854
Increase (decrease) in:	'	'	'
Accounts payable	-76,240	272,566	3,183,437
Accrued expenses	485,518	942,562	7,227,660
Deferred revenue	'	'	465,287
Net cash used in operating activities	-1,568,727	-905,399	-74,532,805
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Acquisitions of property and equipment	'	-933	-899,733
Net cash used by investing activities	'	-933	-899,733
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Bank overdraft	-89	'	'
Proceeds from issuance of common stock, net	1,100,000	459,800	64,981,775
Proceeds from (payments for) initial public offering of common stock, net	'	'	1,447,829
Proceeds from subordinated related party note	'	'	3,000,000
Payment of note payable	'	'	-3,000,000
Proceeds from notes payable, related party	'	'	505,000
Proceeds from related party advances	180,500	351,492	1,047,992
Proceeds from exercise of stock options	'	'	293,749
Proceeds from notes payable	295,000	63,000	11,915,750
Repayments of notes payable	'	'	-3,533,605
Payment of loan costs	'	'	-1,219,268
Net cash provided in financing activities	1,575,411	874,292	75,439,222
Net increase (decrease) in cash and cash equivalents	6,684	-32,040	6,684
Cash and cash equivalents, beginning of period	'	36,828	'
Cash and cash equivalents, end of period	6,684	4,788	6,684
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'	'
Interest paid	513,986	403,618	2,698,068
Income taxes paid	'	'	'
Non-cash financing activities:	'	'	'
Common stock issued in settlement of notes payable	345,000	570,181	4,597,959
Common stock issued in settlement of accounts payable	149,239	14,000	163,239
Preferred stock issued in settlement of notes payable	$70,000	'	$84,000

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows:
	General
	The accompanying unaudited condensed financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The unaudited condensed financial statements should be read in conjunction with the December 31, 2012 financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K.
	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through September 30, 2013, the Company has accumulated a deficit through its development stage of $117,453,724.
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 323,296,916 and 182,807,340 for the three months ended September 30, 2013 and 2012, respectively and 336,682,241 and 174,169,691 for the nine months ended September 30, 2013 and 2012, respectively.
	Stock Based Compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).
	As of September 30, 2013, there were outstanding stock options to purchase 25,206,532 shares of common stock, 7,544,618 shares of which were vested.
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.
	As of September 30, 2013 and December 31, 2012, three (3) and one (1) customer represented 98% and 97% of the Company’s accounts receivable, respectively.
	For the three and nine month period ended September 30, 2012, the Company’s revenues earned from the sale of products and services were $4,072 and $47,245 respectively from three (3) customers.
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $158,381 and $106,889 for the three months ended September 30, 2013 and 2012, respectively; $494,762 and $297,535 for the nine months ended September 30, 2013 and 2012, respectively and $65,187,814 from August 12, 1999 (date of inception) to September 30, 2013.
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
	Reliance on Key Personnel and Consultants
	The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.
	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Specifically, the Company reclassified advances and accrued expenses due related parties to notes payable related party within current liabilities of the balance sheet.
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.

Going_Concern_Matters

Going Concern Matters	9 Months Ended
	Sep. 30, 2013
Going Concern Matters [Abstract]	'
GOING CONCERN MATTERS	'
	NOTE 2 – GOING CONCERN MATTERS
	The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed financial statements, during nine months ended September 30, 2013, the Company incurred net losses attributable to common shareholders of $2,416,000 and used $1,568,727 in cash for operating activities. As of September 30, 2013, the Company had a working capital deficit (current liabilities in excess of current assets) of approximately $13.4 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory [Abstract]	'
INVENTORY	'
	NOTE 3 – INVENTORY
	Inventory consists of raw materials. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value). During the nine months ended September 30, 2013, the Company wrote-off the full balance of inventory to expense due to obsolescence.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 4 – PROPERTY AND EQUIPMENT
	Property and equipment as of September 30, 2013 and December 31, 2012 is summarized as follows:
		September 30,			December 31,
		2013			2012
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		130,916			130,916
	Computer equipment		54,414			54,414
	Leasehold improvements		362,046			362,046
			899,734			899,734
	Less accumulated depreciation and amortization		(899,242	)		(897,914	)
		$	492		$	1,820
	Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.
	Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Accrued Expenses [Abstract]	'
ACCRUED EXPENSES	'
	NOTE 5 – ACCRUED EXPENSES
	Accrued expenses consisted of the following as of September 30, 2013 and December 31, 2012:
		September 30,		December 31,
		2013		2012
	License and royalty fees	$	2,046,789	$	1,825,675
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,354,043		1,284,705
	Interest payable on notes payable		833,105		1,100,174
	Vendor accruals and other		174,268		120,133
	Employee commissions, compensation, etc.		122,476		400,801
		$	4,530,681	$	4,731,488
	During the nine months ended September 30, 2013, 1,000,000 shares of common stock were issued to one debt holder in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note.

Standby_Equity_Distribution_Ag

Standby Equity Distribution Agreement	9 Months Ended
	Sep. 30, 2013
Standby Equity Distribution Agreement [Abstract]	'
STANDBY EQUITY DISTRIBUTION AGREEMENT	'
	NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT
	On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).
	During this 24-month period, commencing on the date on which the SEC first declared the registration statement effective, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement.
	For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then be irrevocably bound to acquire such shares. The registration statement of the Company's common stock pursuant to the Agreement was declared effective on February 10, 2012 and a Post-Effective Amendment was declared effective on May 7, 2013. On December 1, 2012, the parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.
	During the nine months ended September 30, 2013, the Company issued an aggregate of 12,658,545 shares of its common stock in exchange for $200,000 draw down on the equity line.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	NOTE 7 – NOTES PAYABLE
	Notes payable were comprised of the following as of September 30, 2013 and December 31, 2012:
		September 30,			December 31,
		2013			2012
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			1,000,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		90,000			—
	Total notes payable		1,954,972			2,364,972
	Less unamortized debt discount		(64,562	)		—
	Total notes payable net of unamortized debt discount	$	1,890,410		$	2,364,972
	Seaside Bank
	On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company.
	August 2008 Unsecured Promissory Note
	On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term.
	Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Note holder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.
	The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and has been fully amortized as interest expense ratably over the term of the loan.
	During the nine months ended September 30, 2013, 1,000,000 shares of common stock were issued to the debt holder, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of September 30, 2013 the principle of this note was $500,000.
	Hunton & Williams Notes
	At September 30, 2013 and December 31, 2012, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
	Asher Notes (During this year)
	During the nine months ended September 30, 2013, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”), for the sale of 8% convertible notes in aggregate principal amount of $170,000 (the “Asher Notes”).
	The Asher Notes bear interest at the rate of 8% per annum. As of the quarter ended September 30, 2013 all interest and principal must be repaid nine months from the issuance date, the last note due June 11, 2014. The Notes are convertible into common stock, at Asher’s option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and reset provision.
	The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date which at September 30, 2013 was $118,934. At the inception of the Asher Notes, the Company determined the aggregate fair value of $207,176 of the embedded derivatives.
	The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 163.73%, (3) weighted average risk-free interest rate of 0.09% to 0.17%, (4) expected lives of 0.67 to .77 years, and (5) estimated fair value of the Company’s common stock from $0.011 to $0.0373 per share. The initial fair value of the embedded debt derivative of $207,176 was allocated as a debt discount up to the proceeds of the note ($170,000) with the remainder ($37,176) charged to current period operations as interest expense. For the three and nine months ended September 30, 2013, the Company amortized $53,115 and $105,438 of debt discount to current period operations as interest expense, respectively. As of September 30, 2013 the gross balance of the Asher Notes was $90,000.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 8 — RELATED PARTY TRANSACTIONS
	Lease Guarantee
	The Company’s former Chairman of the Board, Chief Executive Officer and Chief Technology Officer has personally guaranteed the Company’s obligations under its lease for its facilities in Sunrise, Florida and has provided a personal guarantee for the Company credit card, which is for his own use only.
	Advances
	As of September 30, 2013 and December 31, 2012, the Company officers and directors have provided advances in the aggregate of $316,198 and $313,448 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.
	On August 1, 2013, advances in aggregate of $22,750 were converted into a demand promissory note with 5% interest per annum.  On September 30, 2013, the Company issued 1,995,614 shares of common stock in settlement of the $22,750 promissory note.
	On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances.
	Notes payable-related party
	Northstar Biotechnology Group, LLC
	On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.
	On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the Note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
	On September 21, 2012, the Company issued 5,000,000 common stock purchase warrants to Northstar that was treated as Additional interest expense upon issuance.
	On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement whereby the Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.
	In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
	Effective October 1, 2012, the effective interest rate will be 12.85% per annum.  The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum (see Note 14 below).
	In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock; payments of common stock for April 1, 2013 and October 1, 2013 shall be made the fourth quarter of 2013 based on the closing price of the common stock on April 1, 2013 and October 1, 2013 respectively (see Note 14 below).
	As described above, during the nine months ended September 30, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the nine months ended September 30, 2013. On September 30, 2013, the Company issued 8,771,929 shares of its common stock as payment of $100,000 towards cash advances. As of September 30, 2013, the principle of this note was $362,000.
	Officer and Director Notes
	At September 30, 2013 and December 31, 2012, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar loan is paid off.
	On October 9, 2012, the Company issued an aggregate of $1,278,324 promissory notes due October 9, 2013 to officers and directors in settlement of outstanding advances and accrued compensation. The promissory notes bear interest of 5% per annum and due at maturity.
	On August 1, 2013, the Company issued an aggregate of $500,000 promissory notes due on demand to officers and employee in settlement of accrued compensation. The promissory notes bear interest of 5% per annum and due at various maturity dates.
	On September 30, 2013, the Company issued an aggregate of 15,350,876 shares of its common stock in settlement of $175,000 of related party notes payable.
	Subordinated debt, related party
	As of September 30, 2013 and December 31, 2012, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the Northstar note payable described above

Derivative_Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2013
Derivative Liabilities [Abstract]	'
DERIVATIVE LIABILITIES	'
	NOTE 9 — DERIVATIVE LIABILITIES
	Excessive committed shares
	On December 31, 2012, in connection with the previously issued stock options and warrants, the Company had the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.
	On February 4, 2013, in conjunction with the increase in authorized number of shares to 970,000,000, the Company determined it had adequate authorized shares to settle all of these agreements. As such, the Company adjusted the derivative liability to fair value on February 4, 2013 and reclassified the derivative liability to equity. The fair value of the derivative liability of $474,954 (a non-cash item) as of February 4, 2013 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 156.52%; risk free rate: 0.38%; and expected life: 3.5 years. The Company recorded a loss on change in derivative liabilities of $84,907 during the nine months ended September 30, 2013.
	Reset warrants
	On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.
	The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.
	At September 30, 2013, the fair value of the reset provision of $162,103 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 162.57%; risk free rate: 2.64%; and expected life: 9.00 years. The Company recorded a gain on change in derivative liabilities of $59,076 during the nine months ended September 30, 2013.
	Convertible notes
	During the nine months ended September 30, 2013, the Company issued convertible notes (see Note 7 above).
	These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.
	The fair value of the embedded derivatives at September 30, 2013, in the amount of $118,934, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 162.57%, (3) weighted average risk-free interest rate of 0.04%, (4) expected lives of 0.39 to 0.70 years, and (5) estimated fair value of the Company’s common stock of $0.011 per share. The Company recorded a gain on change in derivative liabilities of $65,716 during the nine months ended September 30, 2013.
	Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.
	At September 30, 2013, the aggregate derivative liabilities was valued at $281,037, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 10 – STOCKHOLDERS’ EQUITY
	Preferred stock
	On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 8 above).
	During the nine months ended September 30, 2013, the Company issued an aggregate of 20,000,000 shares of Series A Convertible Preferred Stock for principle payment and settlement of forbearance (see note 8 above).
	Common stock
	On February 4, 2013, the Company amended its Articles of Incorporation to increase the number of authorized shares to 970,000,000, consisting of 20,000,000 $0.001 par value preferred stock and 950,000,000 $0.001 common stock.
	During the nine months ended September 30, 2013, the Company issued an aggregate of 5,061,101 shares of its common stock for settlement of $74,839 of accounts payable. In connection with the settlement, the Company recorded a loss on settlement of debt of $74,401.
	During the nine months ended September 30, 2013, the Company issued 2,500,000 shares of its common stock in connection with the issuance of a note payable.
	During the nine months ended September 30, 2013, the Company issued 39,833,771 shares of its common stock in connection with the settlement and/or conversion of various notes payable.
	During the nine months ended September 30, 2013, the Company issued 44,890,348 shares of its common stock in connection with the settlement of related party notes payable and advances.
	During the nine months ended September 30, 2013, the Company issued 2,532,471 shares of its common stock services rendered valued at $40,519.

Stock_Option_and_Warrants

Stock Option and Warrants	9 Months Ended
	Sep. 30, 2013
Stock Options and Warrants [Abstract]	'
STOCK OPTIONS AND WARRANTS	'
	NOTE 11 — STOCK OPTIONS AND WARRANTS
	Stock Options
	In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.
	In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares of common stock for issuance.
	Effective April 1, 2013, the Board of Directors resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013. Subsequently, this action was rescinded and the repricing date was set for August 5, 2013.
	A summary of options at September 30, 2013 and activity during the year then ended is presented below:
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise Price		Remaining
							Contractual
							Term (in years)
	Options outstanding at January 1, 2012		4,636,318		$	1.2	8.1
	Granted		3,300,000		$	0.04
	Exercised				$
	Forfeited/Expired		(82,942	)	$	5.57
	Options outstanding at December 31, 2012		7,853,376		$	0.67	8.2
	Granted		17,400,000		$	0.016	9.9
	Exercised
	Forfeited/Expired		(46,844	)	$	5.67
	Options outstanding at September 30, 2013		25,206,532		$	0.2	9.1
	Options exercisable at September 30, 2013		7,544,618		$	0.62	7.9
	Available for grant at September 30, 2013		32,600,000
	The following information applies to options outstanding and exercisable at September 30, 2013:
		Options Outstanding								Options Exercisable
		Shares			Weighted-		Weighted-		Shares			Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
					Contractual		Price					Price
					Term
	$0.00 – $0.70		24,194,360			9.4	$	0.04			6,436,627		$	0.08
	$0.71 – $1.28		324,471			4.6	$	0.77			429,290		$	0.76
	$5.25 – $5.67		641,951			2.2	$	5.56			632,951		$	5.57
	$7.69		39,572			2.9	$	7.69			39,572		$	7.69
	$8.47		6,178			3.9	$	8.47			6,178		$	8.47
			25,206,532			9.1	$	0.2			7,544,618		$	0.62
	On August 5, 2013, the Company re-priced options previously issued from 2011 through 2012 for current employees and officers in aggregate of 4,890,000 options with previous exercise prices from $0.03 to $0.21 per share to $0.01694 per share, all other terms remaining unchanged.  The gross change in fair value, determined using the Black Scholes option pricing model, of $1,630 was charged to current period operations.
	On August 1, 2013, the Company issued an aggregate 15,000,000 options to purchase the Company’s common stock at $0.01576 per share, respectively; to employees, exercisable over 4 years.   The fair value of $245,749, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 153.27% and Risk free rate: 2.74%, of which $10,240 was charged to current period operations.
	On September 1, 2013, the Company issued an aggregate 2,400,000 options to purchase the Company’s common stock at $0.01654 per share, respectively; to officers and employees, exercisable immediately. The fair value of $37,823, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 150.98% and Risk free rate: 2.78%, was charged to current period operations.
	The fair value of all options vesting during the three and nine months ended September 30, 2013 of $64,294 and $102,674, respectively, and $20,865 and $56,476 for the three and nine months ended September 30, 2012, respectively was charged to current period operations.
	Warrants
	A summary of common stock purchase warrants at September 30, 2013 and activity during the year then ended is presented below:
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise		Remaining
					Price		Contractual
							Term (in
							years)
	Outstanding at January 1, 2012		32,610,075		$	0.86		3.8
	Issued		42,396,432		$	0.018		5.78
	Exercised		—		$	0
	Forfeited		-933,185		$	0.69
	Outstanding at December 31, 2012		74,073,322		$	0.28		4.5
	Issued		40,954,886		$	0.016		9.2
	Exercised		—		$
	Expired		-2,332,877		$	0.73
	Outstanding at September 30, 2013		112,695,331		$	0.23		6
	Exercisable at September 30, 2013		84,534,199		$	0.16		4.7
	In conjunction with the authorized issuance of common stock, the Company granted approximately 35 million common stock purchase warrants during the nine months ended September 30, 2013.
	The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2013:
		Warrants Outstanding								Warrants Exercisable
		Shares			Weighted-		Weighted-			Shares		Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
Contractual					Price		Price
Term
$0.01 – $0.50		106,441,198			6	$	0.03			79,824,516		$	0.04
$0.52 – $0.68		2,699,675			5.6	$	0.58			2,699,675		$	0.58
$0.70 – $1.62		853,176			6.2	$	0.71			853,176		$	0.71
$5.67 – $7.69		2,701,282			9.1	$	7.55			1,156,832		$	7.35
		112,695,331			6	$	0.23			84,534,199		$	0.15

Commiments_and_Contingencies

Commiments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 12 — COMMITMENTS AND CONTINGENCIES
	Royalty Payments
	The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.
	The Company has entered into various licensing agreements, which include the potential for royalty payments, as follows:
	William Beaumont Hospital
	In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000, the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $200,000 for 2012 and thereafter. As of September 30, 2013, the Company has not made any payments other than the initial payment to acquire the license. At September 30, 2013 and December 31, 2012, the Company’s liability under this agreement was $2,046,789 and $1,825,675, respectively, which is reflected as a component of accrued expenses on the balance sheets (see Note 5). During the nine months ended September 30, 2013 and 2012, the Company incurred expenses of $221,113, $157,500 respectively, and $2,046,789 from August 12, 1999 (date of inception) to September 30, 2013. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $379,289 in accrued expenses as of September 30, 2013.
	Approximate annual future minimum obligations under this agreement as of September 30, 2013 are as follows:
	Year Ending December 31,
	2013	$	52,500
	2014		210,000
	2015		210,000
	Total	$	472,500
	Contingency for Registration of the Company’s common stock
	The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of September 30, 2013 or December 31, 2012.
	Litigation
	The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of September 30, 2013, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2013
Fair Value Measurement [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 13 — FAIR VALUE MEASUREMENT
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of September 30, 2013 or December 31, 2012, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 7 and 9. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 7 and 9 are that of volatility and market price of the underlying common stock of the Company.
	As of September 30, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.
	The derivative liability as of September 30, 2013, in the amount of $281,037 has a level 3 classification.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2013:
		Derivative
		Liability
	Balance, December 31, 2012	$	611,227
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		492,412
	Mark-to-market at September 30, 2013:		(39,885)
	Transfers out of Level 3 upon increase in authorized shares		-474,954
	Transfers out of Level 3 upon conversion of notes payable		-307,763
	Balance, September 30, 2013	$	281,037
	Net Gain for the period included in earnings relating to the liabilities held at September 30, 2013

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 14 — SUBSEQUENT EVENTS
	Subsequent financing
	On October 4, 2013, the Company entered into a Securities Purchase Agreement with Asher Enterprises, Inc. ("Asher"), for the sale of an 8% convertible note in the principal amount of $32,500 (the "Note").
	The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on July 8, 2014. The Note is convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 120% if prepaid during the period commencing on the closing date through 30 days thereafter, (ii) 125% if prepaid 31 days following the closing through 60 days following the closing, (iii) 130% if prepaid 61 days following the closing through 90 days following the closing and (iv) 135% if prepaid 91 days following the closing through 120 days following the closing. (v) 140% if prepaid 121 days following the closing through 150 days following the closing, (vi) 150% if prepaid 121 days following the closing through 180 days following the closing. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
	Northstar Letter Agreement
	The Company and Northstar entered into a limited waiver and forbearance agreement whereby the Company is obligated to issue additional preferred stock in lieu of payment of cash equal to the accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). As of April 1, 2013 and October 1, 2013 the Company owes 5,000,000 shares of Series A Convertible Preferred Stock for accrued and unpaid interest for both of the six month anniversaries of the forbearance agreements for a total of 10,000,000 shares of Series A Convertible Preferred Stock to be issued.
	On November 11, 2013, the Company and Northstar (collectively, the “Parties”) agreed to modify the terms of the October 1, 2012 limited waiver and forbearance agreement whereby the Parties agreed to modify the interest rate on the agreement from 12.85% was modified to 7% effective February 28, 2013.   In addition, the Parties agreed the Company would modify the Series A Preferred Stock to read that each share of Series A Preferred Stock shall have 25 votes on all matters presented to be voted by the holders of common stock which will satisfy the preferred stock  payment due of all accrued and unpaid interest on the outstanding note with Northstar due on April 1, 2013 and October 1, 2013.  Lastly, all payments of accrued and unpaid interest shall be in shares of common stock of the Company and that payments of common stock for April 1, 2013 and October 1, 2013 will be made in the fourth quarter of 2013.
	Issuance of Common Stock
	In October 2013, the Company issued an aggregate of 27,859,747 shares of common stock in connection with stock subscriptions.
	In October 2013, the Company issued an aggregate of 5,493,056 shares of common stock in settlement of $25,312 of notes payable and accrued interest.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Significant Accounting Policies [Abstract]	'
Basis and business presentation	'
	Basis and business presentation
	Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through September 30, 2013, the Company has accumulated a deficit through its development stage of $117,453,724.
Comprehensive Income	'
	Comprehensive Income
	The Company does not have any items of comprehensive income in any of the periods presented.
Net Loss per Common Share, basic and diluted	'
	Net Loss per Common Share, basic and diluted
	The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 323,296,916 and 182,807,340 for the three months ended September 30, 2013 and 2012, respectively and 336,682,241 and 174,169,691 for the nine months ended September 30, 2013 and 2012, respectively.
Stock based compensation	'
	Stock Based Compensation
	The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).
	As of September 30, 2013, there were outstanding stock options to purchase 25,206,532 shares of common stock, 7,544,618 shares of which were vested.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.
	As of September 30, 2013 and December 31, 2012, three (3) and one (1) customer represented 98% and 97% of the Company’s accounts receivable, respectively.
	For the three and nine month period ended September 30, 2012, the Company’s revenues earned from the sale of products and services were $4,072 and $47,245 respectively from three (3) customers.
Reliance on Key Personnel and Consultants	'
	Reliance on Key Personnel and Consultants
	The Company has 4 full-time employees and 1 part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Research and Development	'
	Research and Development
	The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $158,381 and $106,889 for the three months ended September 30, 2013 and 2012, respectively; $494,762 and $297,535 for the nine months ended September 30, 2013 and 2012, respectively and $65,187,814 from August 12, 1999 (date of inception) to September 30, 2013.
Fair Value	'
	Fair Value
	Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
	The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
Derivative Instrument Liability	'
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.
Reclassification	'
	Reclassification
	Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Specifically, the Company reclassified advances and accrued expenses due related parties to notes payable related party within current liabilities of the balance sheet.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed financial position, results of operations or cash flows.

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property and Equipment [Abstract]	'
Summary of property and equipment	'
		September 30,			December 31,
		2013			2012
	Laboratory and medical equipment	$	352,358		$	352,358
	Furniture, fixtures and equipment		130,916			130,916
	Computer equipment		54,414			54,414
	Leasehold improvements		362,046			362,046
			899,734			899,734
	Less accumulated depreciation and amortization		(899,242	)		(897,914	)
		$	492		$	1,820

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses [Abstract]	'
Summary of accrued expenses	'
		September 30,		December 31,
		2013		2012
	License and royalty fees	$	2,046,789	$	1,825,675
	Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,354,043		1,284,705
	Interest payable on notes payable		833,105		1,100,174
	Vendor accruals and other		174,268		120,133
	Employee commissions, compensation, etc.		122,476		400,801
		$	4,530,681	$	4,731,488

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Notes Payable [Abstract]	'
Summary of notes payable	'
		September 30,			December 31,
		2013			2012
	Seaside Bank note payable.	$	980,000		$	980,000
	August 2008 Unsecured Promissory Note		500,000			1,000,000
	Hunton & Williams notes payable		384,972			384,972
	Asher notes payable		90,000			—
	Total notes payable		1,954,972			2,364,972
	Less unamortized debt discount		(64,562	)		—
	Total notes payable net of unamortized debt discount	$	1,890,410		$	2,364,972

Stock_Option_and_Warrants_Tabl

Stock Option and Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Options and Warrants [Abstract]	'
Summary of options and activity	'
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise Price		Remaining
							Contractual
							Term (in years)
	Options outstanding at January 1, 2012		4,636,318		$	1.2	8.1
	Granted		3,300,000		$	0.04
	Exercised				$
	Forfeited/Expired		(82,942	)	$	5.57
	Options outstanding at December 31, 2012		7,853,376		$	0.67	8.2
	Granted		17,400,000		$	0.016	9.9
	Exercised
	Forfeited/Expired		(46,844	)	$	5.67
	Options outstanding at September 30, 2013		25,206,532		$	0.2	9.1
	Options exercisable at September 30, 2013		7,544,618		$	0.62	7.9
	Available for grant at September 30, 2013		32,600,000
Summary of options outstanding and exercisable for stock-based payment awards	'
		Options Outstanding								Options Exercisable
		Shares			Weighted-		Weighted-		Shares			Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
					Contractual		Price					Price
					Term
	$0.00 – $0.70		24,194,360			9.4	$	0.04			6,436,627		$	0.08
	$0.71 – $1.28		324,471			4.6	$	0.77			429,290		$	0.76
	$5.25 – $5.67		641,951			2.2	$	5.56			632,951		$	5.57
	$7.69		39,572			2.9	$	7.69			39,572		$	7.69
	$8.47		6,178			3.9	$	8.47			6,178		$	8.47
			25,206,532			9.1	$	0.2			7,544,618		$	0.62
Summary of warrants and activity	'
		Shares			Weighted-		Weighted-
					Average		Average
					Exercise		Remaining
					Price		Contractual
							Term (in
							years)
	Outstanding at January 1, 2012		32,610,075		$	0.86		3.8
	Issued		42,396,432		$	0.018		5.78
	Exercised		—		$	0
	Forfeited		-933,185		$	0.69
	Outstanding at December 31, 2012		74,073,322		$	0.28		4.5
	Issued		40,954,886		$	0.016		9.2
	Exercised		—		$
	Expired		-2,332,877		$	0.73
	Outstanding at September 30, 2013		112,695,331		$	0.23		6
	Exercisable at September 30, 2013		84,534,199		$	0.16		4.7
Summary of warrants outstanding and exercisable	'
		Warrants Outstanding								Warrants Exercisable
		Shares			Weighted-		Weighted-			Shares		Weighted-
					Average		Average					Average
					Remaining		Exercise					Exercise
					Contractual		Price					Price
					Term
	$0.01 – $0.50		106,441,198			6	$	0.03			79,824,516		$	0.04
	$0.52 – $0.68		2,699,675			5.6	$	0.58			2,699,675		$	0.58
	$0.70 – $1.62		853,176			6.2	$	0.71			853,176		$	0.71
	$5.67 – $7.69		2,701,282			9.1	$	7.55			1,156,832		$	7.35
			112,695,331			6	$	0.23			84,534,199		$	0.15

Commiments_and_Contingencies_T

Commiments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Summary of future minimum obligations under the agreement	'
	Year Ending December 31,
	2013	$	105,000
	2014		210,000
	2015		210,000
	Total	$	525,000

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurement [Abstract]	'
Summary of changes in fair value of the Company's Level 3 financial liabilities	'
		Derivative
		Liability
	Balance, December 31, 2012	$	611,227
	Total (gains) losses
	Initial fair value of debt derivative at note issuance		492,412
	Mark-to-market at September 30, 2013:		(39,885)
	Transfers out of Level 3 upon increase in authorized shares		-474,954
	Transfers out of Level 3 upon conversion of notes payable		-307,763
	Balance, September 30, 2013	$	281,037
	Net Gain for the period included in earnings relating to the liabilities held at September 30, 2013	$	39,885

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended		170 Months Ended		9 Months Ended	12 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2012
			Employees				Accounts Receivable [Member]	Accounts Receivable [Member]	Sales Revenue Goods and Services Net [Member]	Sales Revenue Goods and Services Net [Member]
							Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]
							Customer	Customer	Customer	Customer
Significant Accounting Policies (Textual)	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	98.00%	97.00%	'	'
Number of customer accounted for accounts receivable	'	'	'	'	'	'	3	1	'	'
Revenue	'	$4,072	'	$47,245	$1,269,640	'	'	'	$4,072	$47,245
Number of customers accounted for revenue	'	'	'	'	'	'	'	'	3	3
Deficit accumulated during development stage	117,453,724	'	117,453,724	'	117,453,724	115,037,724	'	'	'	'
Number of fully diluted shares outstanding	323,296,916	182,807,340	336,682,241	174,169,691	'	'	'	'	'	'
Option outstanding to purchase common stock	7,817,852	'	7,817,852	'	7,817,852	'	'	'	'	'
Options vested	7,544,618	'	7,544,618	'	7,544,618	'	'	'	'	'
Number of full time employees	'	'	4	'	'	'	'	'	'	'
Number of part time employees	'	'	1	'	'	'	'	'	'	'
Research and development expense	$158,381	$106,889	$494,762	$297,535	$65,187,814	'	'	'	'	'

Going_Concern_Matters_Details

Going Concern Matters (Details) (USD $)	9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Going Concern Matters (Textual)	'	'	'
Net losses attributable to common shareholders	$2,416,000	'	'
Net cash used in operating activities	-1,568,727	-905,399	-74,532,805
Working capital deficit	$13,400,000	'	$13,400,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of property and equipment	'	'
Laboratory and medical equipment	$352,358	$352,358
Furniture, fixtures and equipment	130,916	130,916
Computer equipment	54,414	54,414
Leasehold improvements	362,046	362,046
Property and equipment, Gross	899,734	899,734
Less accumulated depreciation and amortization	-899,242	-897,914
Property and equipment, net	$492	$1,820

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of accrued expenses	'	'
License and royalty fees	$2,046,789	$1,825,675
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	1,354,043	1,284,705
Interest payable on notes payable	833,105	1,100,174
Vendor accruals and other	174,268	120,133
Employee commissions, compensation, etc.	122,476	400,801
Accrued expenses, Total	$4,530,681	$4,731,488

Accrued_Expenses_Details_Textu

Accrued Expenses (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses (Textual)	'
Accrued interest	$598,125
Common stock [Member]	'
Accrued Expenses (Textual)	'
Amount of debt exchanged for shares	$500,000
Shares issued in conversion of debt	1,000,000
Number of debt holder	1

Standby_Equity_Distribution_Ag1

Standby Equity Distribution Agreement (Details) (USD $)	0 Months Ended	9 Months Ended
	Nov. 02, 2011	Sep. 30, 2013
Standby Equity Distribution Agreement (Textual)	'	'
Funds contributed by Greystone	$1,000,000	'
Period for which funding is provided	'24 months	'
Transaction description of agreement with affiliates	'	'For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement.
Description of purchase price adjustment under equity line	'	'The parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.
Common stock share issued in exchange for $150,000 draw down on the equity line	'	12,658,545
Amount draw down on the equity line due to issuance of common stock	'	$200,000

Notes_Payable_Details

Notes Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Oct. 25, 2010
Summary of notes payable	'	'	'
Total notes payable	$1,954,972	$2,364,972	'
Less unamortized debt discount	-64,562	'	'
Total notes payable net of unamortized debt discount	1,890,410	2,364,972	'
Seaside Bank note payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	980,000	980,000	980,000
August 2008 Unsecured Promissory Note [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	500,000	1,000,000	'
Hunton & Williams notes payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	384,972	384,972	'
Asher notes payable [Member]	'	'	'
Summary of notes payable	'	'	'
Total notes payable	$90,000	'	'

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

9 Months Ended

170 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Aug. 01, 2013

Dec. 31, 2012

Sep. 30, 2013

Oct. 31, 2010

Sep. 30, 2013

Dec. 31, 2012

Oct. 25, 2010

Apr. 30, 2009

Apr. 30, 2009

Aug. 20, 2008

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Jan. 09, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Common stock [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

Seaside Bank note payable [Member]

BlueCrest Loan Amendment [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

August 2008 Unsecured Promissory Note [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

Hunton & Williams notes payable [Member]

IBC Funds note payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Asher notes payable [Member]

Common stock [Member]

Notes_Payable

Notes_Payable

Note payable one [Member]

Note payable two [Member]

Maximum [Member]

Minimum [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net of unamortized debt discount

$64,562

'

$64,562

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

1,954,972

'

1,954,972

'

2,364,972

'

'

980,000

980,000

980,000

'

'

'

500,000

1,000,000

'

384,972

384,972

'

'

'

90,000

90,000

'

'

'

Common stock issued in connection with issuance of a note payable, Shares

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

8.00%

'

8.00%

5.00%

8.00%

'

'

'

'

4.25%

'

'

13.50%

'

'

'

8.00%

8.00%

'

'

8.00%

8.00%

8.00%

'

'

'

Notes payable, net of debt discount

1,890,410

'

1,890,410

'

2,364,972

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of notes payable

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings from third party pursuant to terms of unsecured promissory note and agreement

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

31-May-10

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from private placement

'

'

'

'

'

'

'

'

'

'

'

'

19,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Occurrence period of repayment of loan

'

'

'

'

'

'

'

'

'

'

'

'

'Within 12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

451,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

$0.53

$0.53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant issued

'

'

'

'

'

'

'

'

'

'

'

'

195,694

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

Outstanding notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

61,150

323,822

'

'

'

'

'

'

Accrued interest

598,125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in conversion of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Amount of debt exchanged for shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

Gain (loss) on settlement of note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

1,078,625

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expected term

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Notes are convertible into common stock, at Asher's option, at a 42% to 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

'

'

'

Percentage of discount to the lowest closing price prior to conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45.00%

42.00%

Fair value of embedded derivatives

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

198,987

207,176

207,176

'

'

'

Recorded fair value of derivatives and faire value of each subsequent reporting date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,934

118,934

'

'

'

Amortization of debt discount

295,750

382,693

1,907,318

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,115

105,438

'

'

'

Interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,176

'

'

'

Dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

163.73%

154.80%

Risk free rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.17%

0.09%

Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 months 7 days

'8 months 1 day

Estimated fair value of the Company's common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

$0.04

$0.02

Notes payable, Principle value

'

'

'

'

'

'

'

'

'

'

'

'

'

$500,000

'

'

'

'

'

'

'

$170,000

$170,000

'

'

'

Related_Party_Transaction_Deta

Related Party Transaction (Details) (USD $)

9 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2013

Aug. 01, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Oct. 05, 2012

Feb. 28, 2013

Oct. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Oct. 02, 2012

Feb. 29, 2012

Mar. 30, 2012

Oct. 09, 2012

Sep. 30, 2013

Aug. 01, 2013

Dec. 31, 2012

Nov. 30, 2012

Oct. 22, 2012

Jun. 04, 2011

Common stock [Member]

Preferred stock [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Northstar Biotechnology Group, LLC Promissory Note [Member]

Promissory Note [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Officer and Director [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances, related party

$316,198

$22,750

$313,448

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal amount of the Loan

'

'

'

'

'

'

'

'

362,000

'

'

544,267

'

'

'

'

'

'

'

'

Repayment terms

'

'

'

'

'

'

'

'

'

'

'

'

'The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.

'

'

'

'

'

'

'

Series A convertible preferred stock issued in exchange for payments

'

'

'

'

'

'

'

'

5,000,000

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

Common stock issued in exchange for payments

'

'

'

'

'

'

'

'

10,000,000

'

10,000,000

'

'

'

'

'

'

'

'

'

Value of debt outstanding

'

'

'

'

'

'

'

'

210,000

'

210,000

'

'

'

'

'

'

'

'

'

Percentage of revenues to be received as royalty

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

12.85%

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock issued for penalty settlement

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

Fair value for Preferred Stock

'

'

'

'

'

'

'

'

274,050

'

'

'

'

'

'

'

'

'

'

'

Subordinated debt, related party

1,500,000

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

8.00%

5.00%

8.00%

'

'

'

'

'

'

'

'

'

'

5.00%

8.00%

5.00%

8.00%

'

'

'

Subordinated notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

125,000

140,000

Face value of note

'

'

'

'

'

'

'

'

'

'

'

'

'

1,278,324

'

500,000

'

'

'

'

Debt instrument, Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

9-Oct-13

'

'

'

'

'

'

Common stock issued in settlement of promissory notes

'

22,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in settlement of promissory note,shares

'

1,995,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued as payment,shares

8,771,929

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advances of cash

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Voting Rights

'

'

'

'

'

'

'

'25 votes

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Voting Rights

'

'

'

'

'

'

'

'20 votes

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in settlement of related party notes payable,Shares

'

'

'

44,890,348

'

'

'

'

'

'

'

'

'

'

15,350,876

'

'

'

'

'

Common stock issued in settlement of related party notes payable

$537,750

'

'

$44,890

'

'

'

'

'

'

'

'

'

'

$175,000

'

'

'

'

'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	0 Months Ended	9 Months Ended	2 Months Ended	9 Months Ended		9 Months Ended
	Feb. 04, 2013	Sep. 30, 2013	Oct. 31, 2012	Sep. 30, 2013	Oct. 01, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	Excessive Committed Shares [Member]	Excessive Committed Shares [Member]	Reset Warrants [Member]	Reset Warrants [Member]	Reset Warrants [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]
							Minimum [Member]	Maximum [Member]
Derivative Liabilities (Textual)	'	'	'	'	'	'	'	'
Increase in common stock, shares, authorized	970,000,000	'	'	'	'	'	'	'
Fair value of derivative liability	$474,954	'	'	$162,103	'	$648,331	'	'
Fair value of embedded derivatives	'	'	'	'	'	118,934	'	'
Dividend yield	0.00%	'	'	0.00%	'	0.00%	'	'
Expected volatility	156.52%	'	'	161.86%	'	162.57%	'	'
Risk free rate	0.38%	'	'	2.64%	'	0.04%	'	'
Expected Term	'3 years 6 months	'	'	'9 years	'	'	'4 months 21 days	'8 months 12 days
Loss on change in derivative liabilities	'	$84,907	'	$59,076	'	$65,716	'	'
Common stock purchase warrants issued	'	'	15,000,000	'	'	'	'	'
Exercise price of warrant	'	'	'	'	0.014	'	'	'
Warrants exercisable period	'	'	'	'	'10 years	'	'	'
Fair value of common stock	'	'	'	'	'	$0.01	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended				1 Months Ended			9 Months Ended
	Sep. 30, 2013	Feb. 04, 2013	Dec. 31, 2012	Aug. 17, 2012	Aug. 17, 2012	Sep. 30, 2013	Feb. 04, 2013	Sep. 30, 2013	Feb. 04, 2013
				Votes	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Common stock [Member]	Common stock [Member]
Stockholders Equity (Textual)	'	'	'	'	'	'	'	'	'
Preferred stock designated as Series A Convertible Preferred Stock	'	'	'	'	5,000,000	20,000,000	'	'	'
Number of votes hold by the holder per common share issued in conversion of preferred stock	'	'	'	20	'	'	'	'	'
Preferred stock shares increased	'	'	'	'	20,000,000	'	'	'	'
Increased number of authorized capital, shares	'	970,000,000	'	'	'	'	20,000,000	'	950,000,000
Preferred stock, par value	$0.00	$0.00	$0.00	'	'	'	'	'	'
Common stock, par value	$0.00	$0.00	$0.00	'	'	'	'	'	'
Common stock issued in settlement of accounts payable, Shares	'	'	'	'	'	'	'	5,061,101	'
Common stock issued in settlement of accounts payable	$149,240	'	'	'	'	'	'	$74,839	'
Loss on settlement of debt	'	'	'	'	'	'	'	$74,401	'
Common stock issued in connection with issuance of a note payable, Shares	'	'	'	'	'	'	'	2,500,000	'
Common stock issued in connection with settlement of note payable	'	'	'	'	'	'	'	39,833,771	'
Preferred Stock, voting rights	'	'	'	'	'20 votes	'	'	'	'
Common Stock, Voting Rights	'	'	'	'	'25 votes	'	'	'	'

Stock_Option_and_Warrants_Deta

Stock Option and Warrants (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of options and activity	'	'	'
Granted, shares	15,000,000	'	'
Options outstanding, Balance	7,817,852	'	'
Exercised, Weighted - Average Exercise Price	$0.02	'	'
Stock Options [Member]	'	'	'
Summary of options and activity	'	'	'
Options outstanding, Beginning Balance	7,853,376	4,636,318	'
Granted, shares	17,400,000	3,300,000	'
Exercised, Shares	'	'	'
Forfeited/Expired, Shares	-46,844	-82,942	'
Options outstanding, Balance	25,206,532	7,853,376	4,636,318
Options Exercisable, Shares	7,544,618	'	'
Available for grant, Shares	32,600,000	'	'
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.67	$1.20	'
Granted, Weighted - Average Exercise Price	$0.02	$0.04	'
Exercised, Weighted - Average Exercise Price	'	'	'
Forfeited/Expired, Weighted - Average Exercise Price	$5.67	$5.57	'
Options outstanding, Weighted - Average Exercise Price, Balance	$0.20	$0.67	$1.20
Options exercisable, Weighted - Average Exercise Price	$0.62	'	'
Options Excercised, Weighted - Average Remaining Contractual Term	'9 years 10 months 24 days	'	'
Options outstanding, Weighted - Average Remaining Contractual Term (in years)	'9 years 1 month 6 days	'8 years 2 months 12 days	'8 years 1 month 6 days
Options exercisable, Weighted - Average Remaining Contractual Term (in years)	'7 years 10 months 24 days	'	'

Stock_Option_and_Warrants_Deta1

Stock Option and Warrants (Details 1) (Stock Options [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Options outstanding and exercisable for stock-based payment awards	'
Options Outstanding, Shares	25,206,532
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years 1 month 6 days
Options Outstanding, Weighted- Average Exercise Price	$0.20
Options Exercisable, Shares	7,544,618
Options Exercisable, Weighted-Average Exercise Price	$0.62
$0.00 - $0.70 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0
Range of Exercise Prices, Maximum	$0.70
Options Outstanding, Shares	24,194,360
Options Outstanding, Weighted-Average Remaining Contractual Term	'9 years 4 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$0.04
Options Exercisable, Shares	64,366,247
Options Exercisable, Weighted-Average Exercise Price	$0.08
$0.71 - $1.28 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$0.71
Range of Exercise Prices, Maximum	$1.28
Options Outstanding, Shares	324,471
Options Outstanding, Weighted-Average Remaining Contractual Term	'4 years 7 months 6 days
Options Outstanding, Weighted- Average Exercise Price	$0.77
Options Exercisable, Shares	429,290
Options Exercisable, Weighted-Average Exercise Price	$0.76
$5.25 - $5.67 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices, Minimum	$5.25
Range of Exercise Prices, Maximum	$5.67
Options Outstanding, Shares	641,951
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years 2 months 12 days
Options Outstanding, Weighted- Average Exercise Price	$5.56
Options Exercisable, Shares	632,951
Options Exercisable, Weighted-Average Exercise Price	$5.57
$7.69 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices	$7.69
Options Outstanding, Shares	39,572
Options Outstanding, Weighted-Average Remaining Contractual Term	'2 years 10 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$7.69
Options Exercisable, Shares	39,572
Options Exercisable, Weighted-Average Exercise Price	$7.69
$8.47 [Member]	'
Options outstanding and exercisable for stock-based payment awards	'
Range of Exercise Prices	$8.47
Options Outstanding, Shares	6,178
Options Outstanding, Weighted-Average Remaining Contractual Term	'3 years 10 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$8.47
Options Exercisable, Shares	6,178
Options Exercisable, Weighted-Average Exercise Price	$8.47

Stock_Option_and_Warrants_Deta2

Stock Option and Warrants (Details 2) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of warrants and activity	'	'
Exercised, Weighted - Average Exercise Price	$0.02	'
Options outstanding, Balance	7,817,852	'
Warrant [Member]	'	'
Summary of warrants and activity	'	'
Options outstanding, Beginning Balance	74,073,322	32,610,075
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$0.28	$0.86
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	'4 years 6 months	'3 years 9 months 18 days
Shares, issued	40,954,886	42,396,432
Warrants, Weighted-Average Exercise Price	$0.02	$0.02
Warrants, Weighted Average Remaining Contractual Term (in years)	'9 years 2 months 12 days	'5 years 9 months 11 days
Exercised, Shares	'	'
Exercised, Weighted - Average Exercise Price	'	$0
Forfeited/Expired, Shares	-2,332,877	-933,185
Forfeited/Expired, Weighted - Average Exercise Price	$0.73	$0.69
Options outstanding, Balance	112,695,331	74,073,322
Options outstanding, Weighted - Average Exercise Price, Balance	$0.23	$0.28
Options outstanding, Weighted - Average Remaining Contractual Term	'6 years	'4 years 6 months
Options Exercisable, Shares	84,534,199	'
Options exercisable, Weighted - Average Exercise Price	$0.16	'
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	'4 years 8 months 12 days	'

Stock_Option_and_Warrants_Deta3

Stock Option and Warrants (Details 3) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Warrants outstanding and exercisable	'
Warrants Outstanding, Shares	112,695,331
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'3 years 10 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.23
Warrants Exercisable, Shares	84,534,199
Warrants Exercisable, Weighted-Average Exercise Price	$0.15
0.01 - $0.50 [Member]	'
Warrants outstanding and exercisable	'
Range of Exercise Prices, Minimum	$0.01
Range of Exercise Prices, Maximum	$0.50
Warrants Outstanding, Shares	106,441,198
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years
Warrants Outstanding, Weighted- Average Exercise Price	$0.03
Warrants Exercisable, Shares	79,824,516
Warrants Exercisable, Weighted-Average Exercise Price	$0.04
0.52 - $0.68 [Member]	'
Warrants outstanding and exercisable	'
Range of Exercise Prices, Minimum	$0.52
Range of Exercise Prices, Maximum	$0.68
Warrants Outstanding, Shares	2,699,675
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'5 years 7 months 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.58
Warrants Exercisable, Shares	2,699,675
Warrants Exercisable, Weighted-Average Exercise Price	$0.58
0.70 - $1.62 [Member]	'
Warrants outstanding and exercisable	'
Range of Exercise Prices, Minimum	$0.70
Range of Exercise Prices, Maximum	$1.62
Warrants Outstanding, Shares	853,176
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'6 years 2 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$0.71
Warrants Exercisable, Shares	853,176
Warrants Exercisable, Weighted-Average Exercise Price	$0.71
5.67 - $7.69 [Member]	'
Warrants outstanding and exercisable	'
Range of Exercise Prices, Minimum	$5.67
Range of Exercise Prices, Maximum	$7.69
Warrants Outstanding, Shares	2,701,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term	'9 years 1 month 6 days
Warrants Outstanding, Weighted- Average Exercise Price	$7.55
Warrants Exercisable, Shares	1,156,832
Warrants Exercisable, Weighted-Average Exercise Price	$7.35

Stock_Option_and_Warrants_Deta4

Stock Option and Warrants (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 01, 2013
Stock Options and Warrants (Textual)	'	'	'	'	'
Fair value of the option vested	$64,294	$20,865	$102,674	$56,476	'
Shares reserved for future issuance under 2013 Omnibus Plan	'	'	'	'	50,000,000
Options to purchase the Company's common stock	'	'	15,000,000	'	'
Exercise price	'	'	$0.02	'	'
Number of warrants granted	'	'	35,000,000	'	'
Dividend yield	'	'	0.00%	'	'
Volatility	'	'	153.27%	'	'
Risk free rate	'	'	2.74%	'	'
5-Aug-13	'	'	'	'	'
Stock Options and Warrants (Textual)	'	'	'	'	'
Options to purchase the Company's common stock	'	'	4,890,000	'	'
Exercise price	'	'	$0.02	'	'
Gross change in fair value, determined using Black Scholes option pricing model	'	'	$1,630	'	'
1-Sep-13	'	'	'	'	'
Stock Options and Warrants (Textual)	'	'	'	'	'
Options to purchase the Company's common stock	'	'	2,400,000	'	'
Exercise price	'	'	$0.02	'	'
Dividend yield	'	'	0.00%	'	'
Volatility	'	'	150.98%	'	'
Risk free rate	'	'	2.78%	'	'

Commiments_and_Contingencies_D

Commiments and Contingencies (Details) (USD $)	Sep. 30, 2013
Summary of future minimum obligations under the agreement	'
2013	$52,500
2014	210,000
2015	210,000
Total	$472,500

Commiments_and_Contingencies_D1

Commiments and Contingencies (Details Textual) (USD $)	1 Months Ended	9 Months Ended		12 Months Ended			170 Months Ended
	Jun. 30, 2000	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2013
		Employees
Commitments and Contingencies (Textual)	'	'	'	'	'	'	'
Patent expiration period	'2015	'	'	'	'	'	'
Payment made to acquire license	$55,000	'	'	'	'	'	'
Annual license fee payable	10,000	'	'	'	'	'	'
Royalties payable	'2% to 4% of net sales of products that are covered by the patents.	'	'	'	'	'	'
Minimum royalty threshold	'	'	'	200,000	200,000	200,000	'
License and royalty fees	'	2,046,789	'	1,825,675	'	'	2,046,789
License expenses incurred	'	221,113	157,500	'	'	'	2,046,789
Accrued interest for past due commitment under license agreement	'	'At 2% over the prime rate.	'	'	'	'	'
Accrued expenses	'	379,289	'	'	'	'	379,289
Number of persons with continuing right to rescission	'	2	'	'	'	'	'
Repurchase consideration for unexercised options	'	'77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted.	'	'	'	'	'
Total rescission liability	'	$371,000	'	'	'	'	$371,000

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	3 Months Ended		9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Summary of changes in fair value of the Company's Level 3 financial liabilities	'	'	'	'	'
Beginning Balance	'	'	$611,227	'	'
Total (gains) losses	'	'	'	'	'
Initial fair value of debt derivative at note issuance	'	'	492,415	'	'
Mark-to-market at June 30, 2013:	'	'	-39,885	'	'
Transfers out of Level 3 upon increase in authorized shares	'	'	-474,954	'	'
Balance	281,307,000	'	281,307,000	'	281,307,000
Net Loss for the period included in earnings relating to the liabilities held at June 30, 2013	$129,298	$20,804	$39,885	$27,265	$134,654

Fair_Value_Measurement_Details1

Fair Value Measurement (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value Measurement (Textual)	'	'
Derivative liability	$281,307,000	$611,227

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Sep. 30, 2013	Aug. 01, 2013	Dec. 31, 2012	Apr. 01, 2013	Nov. 11, 2013	Oct. 30, 2013	Oct. 30, 2013	Oct. 04, 2013	Oct. 01, 2013
				Series A Convertible Preferred Stock [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Northstart Letter Agreement [Member]		Northstart Letter Agreement [Member]	Asher [Member]	Asher [Member]	Series A Convertible Preferred Stock [Member]
									Northstart Letter Agreement [Member]
Subsequent Events (Textual)	'	'	'	'	'	'	'	'	'
Common stock issued in settlement of notes payable and related accrued interest, Shares	'	'	'	5,000,000	'	5,493,056	'	'	10,000,000
Common stock issued in settlement of notes payable and related accrued interest	'	'	'	'	'	$25,312	'	'	'
Convertible Debt, principal amount	'	'	'	'	'	'	'	$32,500	'
Convertible note, interest rate	8.00%	5.00%	8.00%	'	'	'	'	8.00%	'
Debt Instrument, principal and interest repayment date	'	'	'	'	'	'	8-Jul-14	'	'
Convertibel notes description	'	'	'	'	'	'	'The Note is convertible into common stock, at Asher's option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 120% if prepaid during the period commencing on the closing date through 30 days thereafter, (ii) 125% if prepaid 31 days following the closing through 60 days following the closing, (iii) 130% if prepaid 61 days following the closing through 90 days following the closing and (iv) 135% if prepaid 91 days following the closing through 120 days following the closing. (v) 140% if prepaid 121 days following the closing through 150 days following the closing, (vi) 150% if prepaid 121 days following the closing through 180 days following the closing. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.	'	'
Forbearance agreement description	'	'	'	'	'	'	'	'	'
					On November 11, 2013, the Company and Northstar (collectively, the “Parties”) agreed to modify the terms of the October 1, 2012 limited waiver and forbearance agreement whereby the Parties agreed to modify the interest rate on the agreement from 12.85% was modified to 7% effective February 28, 2013.
Preferred Stock, voting rights	'	'	'	'	'	'	'	'	'
					25 votes
Common Stock issued with connection of stock subcriptions	'	'	'	'	'	27,859,747	'	'	'